AUTHOR=Zhao Lu , Mei Qingyun , Yu Yongchao , Wang Na , Zhang Dou , Liao Dongying , Zuo Jinhui , Xie Hongxia , Jia Yingjie , Kong Fanming 

TITLE=Research Progress on RET Fusion in Non-Small-Cell Lung Cancer

JOURNAL=Frontiers in Oncology

VOLUME=Volume 12 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.894214

DOI=10.3389/fonc.2022.894214

ISSN=2234-943X

ABSTRACT=Great progress has been made in the treatment of driver gene positive Non- Small Cell Lung Cancer (NSCLC) in recent years. RET fusion was seen in 0.7% to 2% of NSCLC and was associated with younger age and never-smoker status. The 2021 NSCLC treatment guidelines recommended the treatment of pralsetinib and serpatinib for RET fusion gene-positive phase IV NSCLC. A platinum-containing chemotherapy regimen or immunotherapy can be used after RET inhibitor resistance. The mechanism of drug resistance and the clinical safety require further observation. This review outlines the research progress on the treatment of NSCLC with RET fusion and provide clinical advice for this part of patients.